Strongbridge Biopharma (Strongbridge Biopharma) Cash-to-Debt : 3.51 (As of Jun. 2021)

View and export this data going back to 2013. Start your Free Trial

What is Strongbridge Biopharma Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Strongbridge Biopharma's cash to debt ratio for the quarter that ended in Jun. 2021 was 3.51.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Strongbridge Biopharma could pay off its debt using the cash in hand for the quarter that ended in Jun. 2021.

The historical rank and industry rank for Strongbridge Biopharma's Cash-to-Debt or its related term are showing as below:

SBBP' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.85 Med: 51.66 Max: No Debt
Current: 3.51

During the past 8 years, Strongbridge Biopharma's highest Cash to Debt Ratio was No Debt. The lowest was 0.85. And the median was 51.66.

SBBP's Cash-to-Debt is not ranked
in the Biotechnology industry.
Industry Median: 6.49 vs SBBP: 3.51

Strongbridge Biopharma Cash-to-Debt Historical Data

The historical data trend for Strongbridge Biopharma's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Strongbridge Biopharma Cash-to-Debt Chart

Strongbridge Biopharma Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Cash-to-Debt

Get a 7-Day Free Trial

3.63

1.52

No Debt

53.72

4.81

Strongbridge Biopharma Quarterly Data
	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21
Cash-to-Debt	Get a 7-Day Free Trial															8.10	10.65	4.81	4.15	3.51

Competitive Comparison of Strongbridge Biopharma's Cash-to-Debt

For the Biotechnology subindustry, Strongbridge Biopharma's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Strongbridge Biopharma's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Strongbridge Biopharma's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Strongbridge Biopharma's Cash-to-Debt falls into.

Strongbridge Biopharma Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Strongbridge Biopharma's Cash to Debt Ratio for the fiscal year that ended in Dec. 2020 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	87.522	/	(0.415	+	17.779)
	=	4.81

Strongbridge Biopharma's Cash to Debt Ratio for the quarter that ended in Jun. 2021 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	63.774	/	(1.145	+	17.002)
	=	3.51

Strongbridge Biopharma (NAS:SBBP) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Strongbridge Biopharma Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Strongbridge Biopharma's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Strongbridge Biopharma (Strongbridge Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Strongbridge Biopharma PLC (NAS:SBBP) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

900 Northbrook Drive, Suite 200, Trevose, PA, USA, 19053

Website

http://www.strongbridgebio.com

Strongbridge Biopharma PLC is a biopharmaceutical company which focuses on the development, in-licensing, acquisition, and commercialization of various complementary products and product candidates that target rare diseases. The product portfolio of the group includes COR-003(levoketoconazole) and COR-005 (veldoreotide). COR-003 is a cortisol inhibitor which is used for the treatment of endogenous cushing's syndrome and COR-005 a novel somatostatin analog, which is used for the treatment of acromegaly. In addition, it is also developing BP-2002 (gene modified probiotic) which will be used for the treatment of Diabetes. Geographically, business activity of the firm is primarily functioned through the United States.

Executives

David N Gill	director	C/O NXSTAGE MEDICAL INC. (NXTM), 439 SOUTH UNION STREET, 5TH FLOOR, LAWRENCE MA 01843
Cdk Associates, L.l.c.	10 percent owner	C/O CAXTON CORPORATION, 731 ALEXANDER ROAD, BUILDING #2, PRINCETON NJ 08540
Bruce Kovner	10 percent owner	C/O CAXTON ASSOCIATES, 500 PARK AVENUE, NEW YORK NY 10022
Caxton Corp	10 percent owner	731 ALEXANDER ROAD, BUILDING 2, SUITE 500, PRINCETON NJ 08540
John Johnson	director, officer: Chief Executive Officer	DENDREON CORPORATION, 1301 2ND AVENUE, SEATTLE WA 98101
Garheng Kong	director	712 COLLEGE AVENUE, MENLO PARK CA 94025
Jeffrey W Sherman	director	C/O IDM PHARMA, INC., 9 PARKER, SUITE 100, IRVINE CA 92618
Marten Steen	director	60 LEVERONI COURT, NOVATO CA 94949
Hilde H Steineger	director	900 NORTHBROOK DRIVE, SUITE 200, TREVOSE PA 19053
Stephen J Long	officer: Chief Legal Officer	C R BARD INC 730 CENTRAL AVENUE MURRAY HILL NJ 07974
Fredric J. Cohen	officer: Chief Medical Officer	900 NORTHBROOK DRIVE SUITE 200 TREVOSE PA 19053
Scott L. Wilhoit	officer: Chief Commercial Officer	900 NORTHBROOK DRIVE SUITE 200 TREVOSE PA 19053
Robert Matthew Lutz	officer: Chief Financial Officer	900 NORTHBROOK DRIVE, SUITE 200, TREVOSE PA 19053
Richard S Kollender	officer: Chief Operating Officer	C/O QUAKER BIOVENTURES, CIRA CENTRE, 2929 ARCH STREET, 3RD FLOOR, PHILADELPHIA PA 19104-2868
A Brian Davis	officer: Chief Financial Officer	C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380